PRA Health Sciences, Inc. stock performance trend indicates that the stock price has rallied 8.45% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 5.11% . Looking at the past 52 week period, the stock price is up at 44.74% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of PRA Health Sciences, Inc. has a positive value of 23.48 compared to overall market.PRA Health Sciences, Inc. is having a Relative Strength Index of 51.99 which indicates the stock is not yet over sold or over bought based on the technical indicators.
PRA Health Sciences, Inc. (NASDAQ:PRAH) has tumbled 0.5% during the past week and has dropped 3.13% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.74%. PRA Health Sciences, Inc. (NASDAQ:PRAH) has underperformed the index by 4.23% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
For the current week, the company shares have a recommendation consensus of Buy. PRA Health Sciences, Inc. (NASDAQ:PRAH) : On Friday heightened volatility was witnessed in PRA Health Sciences, Inc. (NASDAQ:PRAH) which led to swings in the share price. The stock opened for trading at $58.86 and hit $59.66 on the upside , eventually ending the session at $59.4, with a gain of 0.7% or 0.41 points. The heightened volatility saw the trading volume jump to 1,379,550 shares. The 52-week high of the share price is $61.92 and the company has a market cap of $3,662 million. The 52-week low of the share price is at $39.25 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.PRA Health Sciences Inc was Upgraded by Avondale to Mkt Perform on Feb 27, 2017. PRA Health Sciences Inc was Upgraded by Credit Suisse to Outperform on Feb 6, 2017.
Company has reported several Insider transactions to the SEC, on Feb 23, 2017, Colin Shannon (President & CEO) sold 100,000 shares at 61.50 per share price.On Aug 17, 2016, Linda Baddour (Executive VP & CFO) sold 69,380 shares at 52.00 per share price.On Aug 15, 2016, David W Dockhorn (Executive VP & CCO) sold 107,257 shares at 49.00 per share price.
PRA Health Sciences Inc Last issued its quarterly earnings results on Feb 22, 2017. The company reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.07. Analyst had a consensus of $0.64. The company had revenue of $413.61 million for the quarter, compared to analysts expectations of $405.04 million. The companys revenue was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.59 EPS.
PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.